Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Abiomed    ABMD

ABIOMED

(ABMD)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/14/2019 03/15/2019 03/18/2019 03/19/2019 03/20/2019 Date
325.61(c) 333.23(c) 333.25(c) 339.36(c) 339.66 Last
227 755 562 779 465 513 351 809 411 140 Volume
0.00% +2.34% +0.01% +1.83% +0.09% Change
More quotes
Financials (USD)
Sales 2019 781 M
EBIT 2019 228 M
Net income 2019 235 M
Finance 2019 506 M
Yield 2019 -
Sales 2020 993 M
EBIT 2020 308 M
Net income 2020 224 M
Finance 2020 770 M
Yield 2020 -
P/E ratio 2019 66,78
P/E ratio 2020 69,29
EV / Sales2019 18,9x
EV / Sales2020 14,6x
Capitalization 15 300 M
More Financials
Company
Abiomed specializes in the development, manufacture and marketing of medical devices to assist or replace the pumping function of the failing heart. Net sales break down by activity as follows: - product sales (96.1%): heart pumps (Impella brand); - service provision (3.8%): including preventive... 
More about the company
Surperformance© ratings of Abiomed
Trading Rating : Investor Rating :
More Ratings
Latest news on ABIOMED
03/19ABIOMED : Impella RP Post-Approval Study Data Presented at ACC 2019
AQ
03/18ABIOMED : Impella RP Post-Approval Study Data Presented at ACC 2019
BU
03/15ABIOMED : Benefits of Heart Recovery with Impella Showcased at ACC 2019
AQ
03/14ABIOMED : Benefits of Heart Recovery with Impella Showcased at ACC 2019
BU
02/22ABIOMED : $100 Million Invested in Clinical Research for Impella
AQ
02/21ABIOMED : $100 Million Invested in Clinical Research for Impella
AQ
02/20ABIOMED : $100 Million Invested in Clinical Research for Impella
BU
02/05ABIOMED INC : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
AQ
02/04ABIOMED INC : Other Events (form 8-K)
AQ
02/01ABIOMED : Impella Connect Achieves Regulatory Milestone
AQ
More news
Analyst Recommendations on ABIOMED
More recommendations
Stock Trading Strategies
ABIOMED - 2018
Good timing based on weekly price data
BUY
More Stock Trading Analysis
Sector news : Advanced Medical Equipment & Technology - NEC
03/18THERMO FISHER SCIENTIFIC : Plans $150 Million Manufacturing Expansion
DJ
03/15INTUITIVE SURGICAL : FDA Clears Intuitive's da Vinci SP for Transoral Otolaryngo..
DJ
03/14GENERAL ELECTRIC : 2019 Adjusted EPS Forecast Below Street Views
DJ
03/11OLYMPUS : whistleblower Woodford wins London pensions lawsuit
RE
03/07GENERAL ELECTRIC : GE Lures New Batch of Investors
DJ
More sector news : Advanced Medical Equipment & Technology - NEC
Chart ABIOMED
Duration : Period :
Abiomed Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABIOMED
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Average target price 435 $
Spread / Average Target 28%
EPS Revisions
Managers
NameTitle
Michael R. Minogue Chairman, President & Chief Executive Officer
David M. Weber Chief Operating Officer
Todd A. Trapp Chief Financial Officer & Vice President
Thorsten Sieß Chief Technology Officer
Seth Bilazarian Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABIOMED4.41%15 300
THERMO FISHER SCIENTIFIC18.84%105 149
DANAHER CORPORATION25.93%91 249
INTUITIVE SURGICAL17.50%64 544
BOSTON SCIENTIFIC CORPORATION8.01%52 625
ILLUMINA3.59%44 950